Trials / Completed
CompletedNCT05402020
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
Effectiveness of Maintenance Treatment With Tiotropium + Olodaterol in Comparison to Inhaled Corticosteroids + Long-acting β2 Agonists in COPD Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 17,018 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The real world study aims to assess effectiveness and safety profile between tiotropium/olodaterol (Tio/Olo) and inhaled corticosteroids(ICS) / Long-acting β2-agonists (LABA) in patients with chronic obstructive pulmonary disease (COPD) in Taiwan. The data used in this study will come from the Taiwan National Health Insurance (NHI) claims data between 2014 and 2019.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tiotropium (Tio) | Tiotropium (Tio) |
| DRUG | Inhaled corticosteroids (ICS) | Inhaled corticosteroids (ICS) |
| DRUG | Olodaterol (Olo) | Olodaterol (Olo) |
| DRUG | Long-acting β2-agonists (LABA) | Long-acting β2-agonists (LABA) |
Timeline
- Start date
- 2022-09-30
- Primary completion
- 2023-02-13
- Completion
- 2023-02-13
- First posted
- 2022-06-02
- Last updated
- 2024-08-09
- Results posted
- 2024-08-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05402020. Inclusion in this directory is not an endorsement.